Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -49.12% and -75.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?